The study explored the biological effectiveness of NCEPBT across several cancer cell lines, including human salivary gland tumour cells, osteosarcoma, tongue squamous cell carcinoma, and malignant ...
Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS study ...
Ainos plans to commence a site initiation visit for the study around April 2025, subject to regulatory approvals. The study aims to further assess the potential of VELDONA in improving salivary gland ...